康柏西普预防严重后巩膜裂伤玻璃体切除术后增生性玻璃体视网膜病变的临床疗效

摘要 目的：探讨玻璃体腔注射康柏西普对于严重后巩膜裂伤患者玻璃体切除术后增生性玻璃体视网膜病变发生的预防效果。方法：选取从2018年9月至2020年9月我院收治的40例（40眼）严重后巩膜裂伤患者进行研究，随机分为对照组20眼（行常规巩膜裂伤缝合术及经睫状体平坦部玻璃体切除术）和观察组20眼（行巩膜裂伤缝合术及经睫状体平坦部玻璃体切除术的同时联合玻璃体腔注射康柏西普治疗）。比较两组患者术前及术后的视力、眼压，以及术后增生性玻璃体视网膜病变的发生率、视网膜再脱离的发生率。结果：对照组及观察组术后的最佳矫正视力较术前均提高、术后眼压均正常，观察组术后的增生性玻璃体视网膜病变发生率（15.0 %）明显低于对照组（45.0 %, P<0.05），观察组术后视网膜脱离复发率（5.0 %）低于对照组（30.0 %, P>0.05）。结论：严重后巩膜裂伤患者玻璃体切除术联合玻璃体注射康柏西普治疗能够有效降低增生性玻璃体视网膜病变的发生率和术后视网膜脱离的复发率，还可以改善患者的视力预后。

Clinical Efficacy of Conbercept in the Prevention of Proliferative Vitreoretinopathy after Vitrectomy for Severe Posterior Scleral Laceration

ABSTRACT Objective: To research the clinical effect of intravitreal injection of Conbercept in the prevention of proliferative vitreoretinopathy after vitrectomy for severe posterior scleral laceration. Methods: From September 2018 to September 2020, 40 cases of patients(40 eyes) with severe posterior scleral laceration in our hospital were selected for the study, and they were randomly divided into the control group 20 eyes(treated with conventional scleral laceration suture and pars plana vitrectomy) and the observation group 20 eyes (treated with scleral laceration suture and pars plana vitrectomy combined with intravitreal injection of Conbercept). The visual acuity and intraocular pressure were compared between the two groups before and after treatment, and the incidence of proliferative vitreoretinopathy and retinal redetachment were compared between the two groups after treatment. Results: After treatment, the best corrected visual acuity was significantly higher than that before treatment in both groups, and the intraocular pressure was normal in two groups. The incidence of proliferative vitreoretinopathy in the observation group(15.0 %) was significantly lower than that in the control group (45.0 %, P<0.05), and the recurrence rate of retinal detachment in the observation group(5.0 %) was lower than that in the control group (30.0 %, P>0.05). Conclusion: Vitrectomy combined with intravitreal injection of Conbercept for severe posterior scleral laceration can effectively reduce the incidence of proliferative vitreoretinopathy and the recurrence rate of postoperative retinal detachment, and improve the visual prognosis of patients.